Erratum to: Angiogenesis DOI 10.1007/s10456-014-9420-y {#Sec1}
======================================================

The author wishes to correct the errors in Table [1](#Tab1){ref-type="table"} of the original publication.Table 1Randomised trials of anti-angiogenic agents cited in this articleIndicationTreatmentTrial identifier and citationOutcome*Breast cancer*Metastatic 1st linePaclitaxel ± bevacizumabE2100 \[40\]Improvement in PFS not OSDocetaxel ± bevacizumab (HER-2 negative population)AVADO \[41\]Improvement in PFS, OS NACapecitabine, taxane or anthracycline ± bevacizumab (HER-2 negative population)RIBBON-1 \[42\]Improvement in PFS but not in OSDocetaxel and trastuzumab ± bevacizumab (HER-2 positive population)AVEREL \[104\]No improvement in PFS, OS NADocetaxel ± sunitinib (HER-2 negative population)Sun 1064 \[45\]No improvement in PFS or OSPaclitaxel ± bevacizumab or sunitinib (HER-2 negative population)SUN 1094 \[46\]Inferior PFS for sunitinib armMetastatic 2nd line and beyondCapecitabine ± bevacizumabAVF2119 \[39\]No improvement in PFS or OSCapecitabine, taxane, gemcitabine, or vinorelbine ± bevacizumab (HER-2 negative population)RIBBON-2 \[43\]Improvement in PFS but not in OSCapecitabine ± sunitinibNCT00435409 \[44\]No improvement in PFS or OSCapecitabine vs. sunitinib (HER-2 negative population)SUN 1107 \[47\]Inferior PFS and OS for sunitinib armAdjuvantAnthracycline, taxane or both ± bevacizumab (triple negative population)BEATRICE \[58\]No improvement in DFS, OS NANeo-adjuvantDoxorubicin/docetaxel/cyclophosphamide ± bevacizumabNCT00408408 \[63\]Improvement in pathological complete response rate (primary endpoint)Epirubicin/docetaxel/Cyclophosphamide ± bevacizumab (HER-2 negative population)NCT00567554 \[64\]Improvement in pathological complete response rate (primary endpoint)*Colorectal cancer*Metastatic 1st lineIFL ± bevacizumabAVF2107 \[19\]Improvement in OS and PFSFOLFOX or XELOX ± bevacizumabNO16966 \[21\]Improvement in PFSCapecitabine ± bevacizumabAVEX \[22\]Improvement in PFS, OS NAFOLFIRI ± sunitinibSUN1122 \[28\]No improvement in PFSFOLFOX ± vatalanibCONFIRM 1 \[29\]No improvement in PFS or OSMetastatic 2nd line and beyondFOLFOX ± bevacizumabE3200 \[20\]Improvement in OS and PFSFOLFOX ± vatalanibCONFIRM 2 \[30\]Improvement in PFS but not OSFOLFIRI ± afliberceptVELOUR \[27\]Improvement in OS and PFSRegorafenib versus placeboCORRECT \[31\]Improvement in OSContinuation beyond progressionChemotherapy ± bevacizumabML18 147 \[92\]Improvement in OSAdjuvantFOLFOX ± bevacizumabNSABP C-08 \[56\]No improvement in OSFOLFOX or XELOX ± bevacizumabAVANT \[57\]No improvement in OS*Hepatocellular carcinoma*Metastatic 1st lineSorafenib versus placeboNCT00105443 \[17\]Improvement in PFS and OSBrivanib versus sorafenibBRISK-FL \[145\]OS non-inferiority end-point for brivanib versus sorafenib not metMetastatic 2nd lineBrivanib versus placeboBRISK-PS \[146\]Improvement in PFS but not OS*Melanoma*Metastatic 1st linePaclitaxel/carboplatin ± bevacizumabBEAM\*\*\* \[48\]No improvement in PFS or OSPaclitaxel/carboplatin ± sorafenibNCT00110019 \[49\]No improvement in PFS or OSMetastatic 2nd linePaclitaxel/carboplatin ± sorafenibNCT00111007 \[50\]No improvement in PFS or OS*NSCLC*\*Metastatic 1st linePaclitaxel/carboplatin ± bevacizumabNCT00021060 \[32\]Improvement in PFS and OSCisplatin/gemcitabine ± bevacizumabAVAiL \[33\]Improvement in PFS but not OS*Ovarian cancer*Metastatic 1st linePaclitaxel/carboplatin ± bevacizumabICON-7 \[36\]Improvement in PFS, OS NAPaclitaxel/carboplatin ± bevacizumabGOG218 \[37\]Improvement in PFS, OS confounded by cross-overMetastatic 2nd lineGemcitabine/carboplatin ± bevacizumabOCEANS \[38\]Improvement in PFS but not OS*Pancreatic cancer*Metastatic 1st lineGemcitabine ± bevacizumabCALGB 80303 \[51\]No improvement in PFS or OS*PNET*Metastatic 1st lineSunitinib versus placeboNCT00428597 \[18\]Improvement in PFS, OS NA*Prostate cancer*\*\*Metastatic 1st lineDocetaxel/prednisone ± bevacizumabCALGB 90401 \[52\]Improvement in PFS but not OSDocetaxel/prednisone ± afliberceptVENICE \[53\]No improvement in PFS or OS*Renal cancer*Metastatic 1st lineSorafenib versus placeboTARGET \[9\]Improvement in PFS and OSSunitinib versus interferon-alphaNCT00098657 \[11\]Improvement in PFS and OSPazopanib versus placeboNCT00334282 \[13\]Improvement in PFS, OS confounded by cross-overSunitinib versus pazopanibCOMPARZ \[15\]PFS and OS were similarMetastatic 2nd lineAxitinib versus sorafenibAXIS \[16\]Improvement in favour of axitinib for PFS but not OS*DFS* disease-free survival, *FOLFIRI* 5-FU, leucovorin and irinotecan, *FOLFOX* 5-FU, leucovorin and oxaliplatin, *HER-2* human epidermal growth factor receptor-2, *IFL* irinotecan, 5FU and leucovorin, *NA* not available (pending, unknown or not reported), *NSCLC* non-small cell lung cancer, *OS* overall survival, *PNET* pancreatic neuroendocrine tumour, *PFS* progression-free survival, *XELOX* capecitabine and oxaliplatin\* Non-squamous NSCLC only; \*\* castration resistant; \*\*\* randomised phase II study

The content in Table [1](#Tab1){ref-type="table"}, under the section entitled 'Colorectal cancer' has three errors.For the AVF2107 trial, in the treatment column, "FOLFIRI" should be replaced with "IFL"For the NO16966 trial, in the outcome column "Improvement in OS and PFS" should be replaced with "Improvement in PFS" andDefinitions of the abbreviations IFL and XELOX were omitted and have been added to the foot of the table.

The correct Table [1](#Tab1){ref-type="table"} is provided in this Erratum.

The online version of the original article can be found under doi:10.1007/s10456-014-9420-y.
